Quantcast

Latest PTC Therapeutics Stories

2009-12-22 07:00:00

SOUTH PLAINFIELD, N.J., Dec. 22 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the completion of a $50 million financing. The round was led by The Column Group - a new investor - and existing investor Delphi Ventures. The co-lead investors were joined by current investors Credit Suisse First Boston, HBM BioVentures, Novo A/S, Celgene, and other existing and new investors. In conjunction with the Delphi investment, general partner Deepa Pakianathan, Ph.D. will join PTC's...

2009-09-02 07:00:00

SOUTH PLAINFIELD, N.J., Sept. 2 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced an exclusive research collaboration and licensing agreement with Roche for the development of orally bioavailable small molecules utilizing PTC's technology called Gene Expression Modulation by Small-molecules (GEMS(TM)). The collaboration focuses initially on four CNS disease targets to be jointly selected. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) Under the terms of the...

2009-09-02 07:00:00

SOUTH PLAINFIELD, N.J., Sept. 2 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that Celgene Corporation has exercised its option to collaborate on advancing drug discovery efforts on an oncology target addressed through the application of PTC's GEMS(TM) (Gene Expression Modulation by Small-molecules) technology. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) In September 2007, Celgene made a $20 million equity investment in PTC, which included an option for...

2009-08-10 07:00:00

SOUTH PLAINFIELD, N.J., Aug. 10 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has reached a major research milestone in its collaboration with Schering-Plough Corporation (NYSE: SGP) receiving a $2 million payment in connection with the designation of a development candidate for the treatment of hepatitis C virus (HCV) infection. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) The collaboration began in March of 2006 based on PTC's HCV efforts that...

2009-06-15 07:00:00

- Funding supports continued focus on rare disorders - SOUTH PLAINFIELD, N.J., June 15 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the receipt of two government grants to support clinical development programs in rare disorders. The U.S. Department of Defense Neurofibromatosis Research Program has awarded an $822,345 grant to support a new open-label Phase 2 clinical trial of PTC's product candidate PTC299 in neurofibromatosis type 2 (NF2), a rare genetic tumor. Separately,...

2009-06-01 07:00:00

SOUTH PLAINFIELD, N.J., June 1 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that Clare Kennedy has been appointed as Vice President of Commercial Operations. In this role, she will report to Theresa Natalicchio, Senior Vice President, Commercial, and will be responsible for PTC's patient services and distribution functions focusing on product access and reimbursement. (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ) "We are delighted to welcome Clare to our...

2009-02-03 08:47:24

A study by National Institutes of Health (NIH) researchers has revealed surprising new insights into the process used to initially identify an experimental drug now being tested in people with cystic fibrosis and muscular dystrophy. Researchers emphasized that the clinical implications of their findings are unclear, but said the results suggest more work may be needed to make sure the screening process to select promising agents was not flawed by its effects on a firefly enzyme used as a...

2009-02-03 07:00:00

- Ataluren designated as generic name for PTC124 - SOUTH PLAINFIELD, N.J., Feb. 3 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that it has successfully completed patient enrollment of its pivotal clinical trial of PTC124 in patients with nonsense mutation Duchenne and Becker muscular dystrophy (nmDMD/BMD). Accrual was completed two months ahead of schedule. The company also announced today that PTC124 has been issued the generic name, ataluren. (Logo:...

2008-10-24 09:00:07

SOUTH PLAINFIELD, N.J. and ORLANDO, Fla., Oct. 24 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced that results from a randomized Phase 2a European study demonstrated that treatment with the investigational drug PTC124 caused statistically significant improvements in the chloride channel function of children with cystic fibrosis (CF) caused by a particular genetic mutation, called a nonsense mutation. Results from the study were presented today by Isabelle SermetGaudelus, M.D.,...

2008-09-30 09:01:00

SOUTH PLAINFIELD, N.J., Sept. 30 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced promising findings in patients with Duchenne/Becker Muscular Dystrophy (DMD/BMD) at the 13th International World Muscle Society (WMS) Congress. Results from an observational study assessing the utility of the 6-minute walk test (6MWT) as a primary outcome measure in trials of treatment for DMD/BMD showed that the 6MWT clearly differentiates boys with DMD from healthy boys, especially when adjusted...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin